(Q43969171)

English

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

scientific article published on 16 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

vector-borne disease

0 references

human subject research project

0 references

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

Anne M Bridgeman

object named as

Anne Bridgeman

9

0 references

Sarah A. Howles

object named as

Sarah Howles

1

0 references

Andrew James McMichael

11

object named as

Andrew McMichael

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

12

object named as

Lucy Dorrell

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Ana Guimarães-Walker

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Hongbing Yang

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Gemma Hancock

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Katalin di Gleria

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Tony Tarragona-Fiol

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Peter Hayes

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jill Gilmour

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Tomáš Hanke

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

16 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

7306-7312

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

HIV vaccines: new frontiers in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Diversity in the acute CD8 T cell response to vaccinia virus in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Design and pre-clinical evaluation of a universal HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Prime-boost vectored malaria vaccines: progress and prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.077

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.08.077

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43969171&oldid=2105135473"